MRSN - Mersana Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
44,576
10,594
17,545
25,171
10,359
Cost of Revenue
-
-
-
-
-
Gross Profit
-
-
-
-
-
Operating Expenses
Research Development
63,905
59,915
46,700
32,008
21,353
Selling General and Administrative
17,168
16,334
10,462
6,984
5,347
Total Operating Expenses
81,073
76,249
57,162
38,992
26,700
Operating Income or Loss
-36,497
-65,655
-39,617
-13,821
-16,341
Interest Expense
-
-
-
-
-
Total Other Income/Expenses Net
-
1,398
0
0
-89
Income Before Tax
-34,671
-64,257
-38,707
-13,700
-16,428
Income Tax Expense
-
-
-
-
-
Income from Continuing Operations
-34,671
-64,257
-38,707
-13,700
-16,428
Net Income
-34,671
-64,257
-38,707
-13,700
-16,428
Net Income available to common shareholders
-34,671
-64,257
-38,707
-13,700
-16,428
Reported EPS
Basic
-
-2.79
-3.22
-1.01
-0.94
Diluted
-
-2.79
-3.22
-1.01
-0.94
Weighted average shares outstanding
Basic
-
23,032
12,023
13,586
17,493
Diluted
-
23,032
12,023
13,586
17,493
EBITDA
-
-65,655
-38,689
-13,166
-16,044